Compare GERN & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | URG |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 699.3M |
| IPO Year | N/A | 2006 |
| Metric | GERN | URG |
|---|---|---|
| Price | $1.29 | $1.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.17 | ★ $2.57 |
| AVG Volume (30 Days) | 12.2M | ★ 14.9M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,207,000.00 |
| Revenue This Year | $26.91 | $200.42 |
| Revenue Next Year | $43.75 | $98.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $1.00 |
| 52 Week High | $2.01 | $2.35 |
| Indicator | GERN | URG |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 42.46 |
| Support Level | $1.22 | $1.23 |
| Resistance Level | $1.30 | $1.79 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 80.00 | 5.71 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.